Form 8-K - Current report:
SEC Accession No. 0001493152-23-008494
Filing Date
2023-03-22
Accepted
2023-03-22 13:28:59
Documents
16
Period of Report
2023-03-21
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48055
2 ex3-1.htm EX-3.1 12185
3 ex99-1.htm EX-99.1 19745
4 logo.jpg GRAPHIC 11429
  Complete submission text file 0001493152-23-008494.txt   323767

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ptix-20230321.xsd EX-101.SCH 3721
6 XBRL DEFINITION FILE ptix-20230321_def.xml EX-101.DEF 26547
7 XBRL LABEL FILE ptix-20230321_lab.xml EX-101.LAB 36501
8 XBRL PRESENTATION FILE ptix-20230321_pre.xml EX-101.PRE 25171
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5333
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 23752423
SIC: 2834 Pharmaceutical Preparations